A drug for autoimmune disease Sjögren's syndrome, picked up by Novartis when it bought MorphoSys for $2.9 billion last year, has hit the target in a pair of phase 3 trials. Ianalumab (VAY736), a drug ...
Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...
IgA is the most abundant isotype antibody in the intestinal mucosa, where it provides a first line of immune protection against commensal, ingested and sexually transmitted agents. IgA uses a ...
B cells are a subtype of lymphocyte. They form part of the adaptive immune response and mediate humoral immunity. B cells can produce high-affinity antibodies and generate immunological memory. Aging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results